Using ultrasound for real-time imaging in uterine cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the feasibility of using transrectal ultrasound (TRUS) images of the female pelvis to enhance a Magnetic Resonance Imaging (MRI)-TRUS fusion-based needle navigation system for image-guided brachytherapy in uterine cancer. The approach involves integrating TRUS with MRI to improve the precision of needle placement during treatment. The study will assess the effectiveness of this technology in both intact and post-hysterectomy patients, utilizing a proprietary 3D semi-robotic navigation system developed by Eigen Health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically proven invasive primary squamous, adenosquamous, or adenocarcinoma of the uterine cervix, (recurrent or medically inoperable) uterine adenocarcinoma.
* Treatment plan must include curative-intent definitive radiation that includes brachytherapy treatments with or without concurrent chemotherapy
* Adults ≥ 18 years of age
* ECOG Performance Status 0-2

Exclusion Criteria:

* Patients with active rectal bleeding or rectal ulcer

Where it's running

• Duke Cancer Center
  Durham, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Dianda Ayala-Peacock, MD — Duke University Health System (DUHS)
• Study coordinator: Kaitlin Bailey, BNS RN
• Email: Kaitlin.Bailey@duke.edu
• Phone: (919) 668-3726

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• KQB368 as a single-drug treatment for adults with advanced solid tumors

  This study tests whether taking KQB368 by mouth every day can help shrink tumors and is safe for adults with advanced solid cancers.

  Recruiting at 14 sites Phase 1 Kumquat Biosciences Inc. · Los Angeles, California and 13 other locations · NCT07542704

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

• Initial testing of an educational approach to genetic services for families at risk of Lynch syndrome

  This pilot study tests whether an information letter alone or with a booklet helps at-risk relatives decide about pursuing genetic services for Lynch syndrome.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT07106359

• Molecular and cellular analysis of uterine lavage from gynecologic surgery

  This will try a new uterine lavage catheter to collect samples from up to 50 adults having gynecologic surgery to see what cells are present.

  Recruiting Stanford University · Palo Alto, California · NCT07044505

• Zanzalintinib with paclitaxel for recurrent high-grade uterine cancer

  This trial tests whether adding zanzalintinib to paclitaxel is safe and helps people with recurrent high-grade uterine (endometrial) cancer respond to treatment.

  Recruiting at 2 sites Phase 1 Washington University School of Medicine · San Francisco, California and 3 other locations · NCT06795009

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.